Bonomini V, Colì L, Feliciangeli G, Nanni Costa A, Scolari M P
Institute of Nephrology, St. Orsola University Hospital, Bologna, Italy.
Int J Artif Organs. 1994 Jul;17(7):392-8.
A long-term retrospective evaluation (5 years) compares two groups of RDT patients (group 1 on continuous treatment with cellulosic membranes and group 2 with synthetic membranes) regarding survival, general clinical morbidity, and beta 2M-related morbidity. The results showed no significant long-term differences between the groups either for survival or general morbidity despite some differences in biocompatibility. The higher intradialytic removal of beta 2M by synthetic membranes did not lead to a reduction in either pre-dialysis beta 2M values or beta 2M related morbidity. The higher cost of synthetic over cellulosic membranes and the disappointing of many clinical expectations suggest that the use of such membranes, in association with alternative techniques, should take place only according to certain "elective" indications such as old age, diabetes, vascular instability or intradialytic disequilibrium syndrome.
一项长期回顾性评估（5年）比较了两组接受血液透析滤过（RDT）治疗的患者（第1组使用纤维素膜持续治疗，第2组使用合成膜）在生存率、总体临床发病率以及与β2微球蛋白（beta 2M）相关的发病率方面的情况。结果显示，尽管在生物相容性方面存在一些差异，但两组在生存率或总体发病率上没有显著的长期差异。合成膜在透析过程中对β2M的清除率较高，但这并未导致透析前β2M值或与β2M相关的发病率降低。合成膜相对于纤维素膜成本更高，且许多临床预期令人失望，这表明只有根据某些“选择性”适应症，如老年、糖尿病、血管不稳定或透析失衡综合征等，才应将此类膜与替代技术联合使用。
